TP53 and sarcoma: Furthermore, the high proportion of patients carrying TP53 genetic hits likely stimulates other considerations on the window of therapeutic opportunities in uLMS, since TP53 mutations have been associated with resistance to several cytotoxic therapies including drugs used for patients with sarcomas, such as anthracyclines or antimetabolites [30].